Protalix BioTherapeutics Inc (PLX):企業の財務・戦略的SWOT分析

◆英語タイトル:Protalix BioTherapeutics Inc (PLX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH81688FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Protalix BioTherapeutics Inc (PLX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that is involved in the development and commercialization of recombinant therapeutic proteins. The company’s marketed product, Elelyso (taliglucerase alfa), is an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company also has pipeline product candidates that are intended for the treatment of Fabry disease, cystic fibrosis and NETs related diseases. The company develops its proprietary pipeline of recombinant therapeutic proteins through its proprietary technology, ProCellEx plant cell-based protein expression system. It allows the company to rapidly develop a protein for clinical testing, compared to other protein platforms. Protalix is headquartered in Carmiel, Israel.

Protalix BioTherapeutics Inc Key Recent Developments

Mar 30,2021: Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results
Mar 22,2021: Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021
Dec 30,2020: Protalix BioTherapeutics issues 2020 letter to shareholders
Oct 29,2020: Protalix BioTherapeutics reports third quarter 2020 financial results and provides business update
Oct 29,2020: Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Protalix BioTherapeutics Inc – Key Facts
Protalix BioTherapeutics Inc – Key Employees
Protalix BioTherapeutics Inc – Key Employee Biographies
Protalix BioTherapeutics Inc – Major Products and Services
Protalix BioTherapeutics Inc – History
Protalix BioTherapeutics Inc – Company Statement
Protalix BioTherapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Protalix BioTherapeutics Inc – Business Description
R&D Overview
Protalix BioTherapeutics Inc – Corporate Strategy
Protalix BioTherapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Protalix BioTherapeutics Inc – Strengths
Protalix BioTherapeutics Inc – Weaknesses
Protalix BioTherapeutics Inc – Opportunities
Protalix BioTherapeutics Inc – Threats
Protalix BioTherapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Protalix BioTherapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 30, 2021: Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results
Mar 22, 2021: Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021
Dec 30, 2020: Protalix BioTherapeutics issues 2020 letter to shareholders
Oct 29, 2020: Protalix BioTherapeutics reports third quarter 2020 financial results and provides business update
Oct 29, 2020: Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30
Sep 08, 2020: Protalix BioTherapeutics regains compliance with NYSE American Continued Listing Standards
Aug 10, 2020: Protalix BioTherapeutics reports second quarter 2020 financial results and provides business update
Jun 08, 2020: Protalix BioTherapeutics appoints Yael Hayon, Ph.D. as its new Vice President, Research and Development
Jun 01, 2020: Protalix BioTherapeutics reports first quarter 2020 financial results and business update
Mar 16, 2020: Protalix Biotherapeutics announces feasibility study with Kirin Holdings on the production of a novel complex protein
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Protalix BioTherapeutics Inc, Key Facts
Protalix BioTherapeutics Inc, Key Employees
Protalix BioTherapeutics Inc, Key Employee Biographies
Protalix BioTherapeutics Inc, Major Products and Services
Protalix BioTherapeutics Inc, History
Protalix BioTherapeutics Inc, Subsidiaries
Protalix BioTherapeutics Inc, Key Competitors
Protalix BioTherapeutics Inc, Ratios based on current share price
Protalix BioTherapeutics Inc, Annual Ratios
Protalix BioTherapeutics Inc, Annual Ratios (Cont...1)
Protalix BioTherapeutics Inc, Interim Ratios
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Protalix BioTherapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Protalix BioTherapeutics Inc (PLX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Regal Hotels International Holdings Ltd.:戦略・SWOT・企業財務分析
    Regal Hotels International Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Regal Hotels International Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Sareum Holdings Plc (SAR)-製薬・医療分野:企業M&A・提携分析
    Summary Sareum Holdings Plc (Sareum) is a drug discovery and development company that produces targeted small molecule therapeutics for treating cancer and autoimmune diseases. The drug research programs of the company are based on its proprietary drug discovery technology, SKIL (Sareum Kinase Inhib …
  • Sygnity SA (SGN):企業の財務・戦略的SWOT分析
    Sygnity SA (SGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Aerostar S.A.:企業の戦略・SWOT・財務情報
    Aerostar S.A. - Strategy, SWOT and Corporate Finance Report Summary Aerostar S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Grupo Nutresa SA (NUTRESA):企業の財務・戦略的SWOT分析
    Grupo Nutresa SA (NUTRESA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Nestle Pakistan Limited:企業の戦略・SWOT・財務情報
    Nestle Pakistan Limited - Strategy, SWOT and Corporate Finance Report Summary Nestle Pakistan Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Bioverativ Inc (BIVV):製薬・医療:M&Aディール及び事業提携情報
    Summary Bioverativ Inc (Bioverativ) is a biotechnology company that discovers, develops, and markets therapeutics for the treatment of hemophilia, and rare blood disorders. Its product portfolio includes Eloctate, which comprises recombinant antihemophilic factor engineered using Fc fusion technolog …
  • Fujicco Co Ltd:企業の戦略・SWOT・財務情報
    Fujicco Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Fujicco Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Pan Orient Energy Corp. (POE):石油・ガス:M&Aディール及び事業提携情報
    Summary Pan Orient Energy Corp (POE) is an independent upstream oil and gas company. The company has interests in onshore oil and gas assets in Thailand and Indonesia. It also has interests in Andora Energy Corporation, which holds properties in Northern Alberta. Its assets in Thailand include Conce …
  • Harvard Pilgrim Health Care Inc:企業の戦略・SWOT・財務情報
    Harvard Pilgrim Health Care Inc - Strategy, SWOT and Corporate Finance Report Summary Harvard Pilgrim Health Care Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Baytex Energy Corp (BTE):石油・ガス:M&Aディール及び事業提携情報
    Summary Baytex Energy Corp (Baytex Energy) is an independent upstream oil and gas company. It conducts the acquisition, development and production of petroleum and natural gas at its properties in the Western Canadian Sedimentary basin and in the Eagle Ford the US. The company’s products include hea …
  • James Fisher and Sons Plc (FSJ):石油・ガス:M&Aディール及び事業提携情報
    Summary James Fisher and Sons Plc (James Fisher) is a service provider for global marine industry and a specialist supplier of engineering services to the energy industry. The company provides comprehensive services such as design and engineering; inspection and monitoring; lifting and handling; mar …
  • Ineos Group AG-石油・ガス分野:企業M&A・提携分析
    Summary Ineos Group AG (Ineos) is a chemical company, which manufactures and sells petrochemicals, specialty chemicals and oil products. The company’s products include engineering thermoplastic resins, chlor-alkali chemicals, PVC products, films and compounds; and melamine resins for coating, specia …
  • RBS Wealth Management:企業の戦略・SWOT・財務情報
    RBS Wealth Management - Strategy, SWOT and Corporate Finance Report Summary RBS Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Gene Techno Science Co Ltd (4584):企業の財務・戦略的SWOT分析
    Summary Gene Techno Science Co Ltd (GTS) develops and markets drug and antibodies for intractable diseases, cancer, and rare diseases. The company develops biological, biosimilar and regenerative medicine in the therapy areas of renal disease, immunological, oncology, ophthalmic, and bone related di …
  • Sutter Health-製薬・医療分野:企業M&A・提携分析
    Summary Sutter Health (Sutter Health) is a non-profit healthcare service provider, which provides health care service through its hospitals, ambulatory surgery centers, cardiac centers, cancer centers, rehabilitation centers and others. It serves communities across Northern California- in the San Fr …
  • Business Development Bank Of Canada:企業の戦略・SWOT・財務分析
    Business Development Bank Of Canada - Strategy, SWOT and Corporate Finance Report Summary Business Development Bank Of Canada - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Sellier & Bellot J.S.C.:企業の戦略・SWOT・財務分析
    Sellier & Bellot J.S.C. - Strategy, SWOT and Corporate Finance Report Summary Sellier & Bellot J.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Nobility Homes Inc:企業の戦略的SWOT分析
    Nobility Homes Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • SQZ Biotechnologies Co:製薬・医療:M&Aディール及び事業提携情報
    Summary SQZ Biotechnologies Co (SQZ) develops cell-based therapies that harness the body’s natural immune system against cancer. The company utilizes CellSqueeze, a technology platform for engineering various cell functions as antigen presenting cells (APCs) for immune modulation to impact oncology …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆